Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: Anthony@Pacific who wrote (3764)	1/12/1999 10:35:00 PM
From: M. Dion	Read Replies (1) \| Respond to of 122087

I can read your mind anthony......here goes.....blonde, buxom, and of course....SHORT....LOL MIKE

To: Anthony@Pacific who wrote (3764)	1/12/1999 10:59:00 PM
From: Smiley	Read Replies (2) \| Respond to of 122087

KERA: The approval was CONDITIONAL and NOT from the FDA. It was from their "outside expert panel" and it was NOT the total unconditional approval they were seeking. It still has to have approval from the FDA. WASHINGTON (Dow Jones)--A federal panel unanimously backed a new, removable corneal implant for improving nearsightedness but attached conditions. KeraVision Inc. (KERA), which makes the device, said the implant is more desirable than laser corrective surgeries because it is reversible and patients heal faster. The panel convened by the U.S. Food and Drug Administration recommended the agency approve KeraVision's Intac implant, which inserts two, thin semicircles into the cornea to change vision. In laser surgery, tissue is removed to correct eyesight. KeraVision said the device is designed to treat the 22 million adults in the U.S. with low to moderate myopia, the medical term for nearsightedness. The FDA will make the final decision about approving the device for use in the U.S. However, the agency usually follows the advice of the outside expert panels it convenes. The panel said KeraVision should be able to promote Intac as reversible "in most but not all cases, based on a small number of patients and short-term follow-up." KeraVision also asked the panel to recommend the FDA allow the company to call Intac adjustable. However, the panel said the company's data didn't support an adjustable claim. The Intac implants, which were studied in three sizes, reshape the curve of the cornea, which changes how light reaches the retina. If the FDA approves, doctors will be able to prescribe Intacs based on the severity of the patient's nearsightedness. Intac implants come in 0.25 mm, 0.30 mm and 0.35 mm sizes. During KeraVision's studies, more complications, including double vision and fluctuating distance vision, occurred with the .35 mm size implants. The panel recommended continued follow-up of patients with the 0.35 mm implants.

To: Anthony@Pacific who wrote (3764)	1/12/1999 11:24:00 PM
From: Rollcast...	Read Replies (1) \| Respond to of 122087

Tony, have you ever commented on RACE? I seem to recall it being mentioned sometime back. thx in advance

To: Anthony@Pacific who wrote (3764)	1/13/1999 12:19:00 AM
From: tool dude	Read Replies (1) \| Respond to of 122087

Look at the volatility in GNET lately could this be another YHOO but with positive earnings. Anthony I'm impresed with the fact your shorting stocks during the most positive stock rise in history and doing quite well.I wonder could you do even better if the markets reverse? LIKE I SAID YOU DA MAN